# TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/tak-875-versus-placebo-or-glimepiride-in-type-2-diabetes-mellitus-a-phase-2/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Charles Burant,Prabhakar Viswanathan,John Marcinak,Charlie Cao,Majid Vakilynejad,Benhuai Xie,Eckhard Leifke |
| Citations | 245 |
| DOI | 10.1016/s0140-6736(11)61879-5 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2163448046 |
| PMID | 22374408 |
| Type | article |
| Year | 2012 |

## Paper authors

- [Eckhard Leifke](https://scholariq.org/researchers/eckhard-leifke/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.